- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2018
- Public Summary Document (PSD) March 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2018 PBAC Meeting - Word
Irinotecan (nanoliposomal) – March 2018
Irinotecan (nanoliposomal): 43 mg in 10 mL Injection; ONIVYDE®
Last updated
29 June 2018